iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype.
Alzheimer’s disease
Amyloid-beta
Astrocytes
Glia
Microglia
Morphology
PSEN2
Pro-inflammatory
iPSC
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
11
11
2022
accepted:
07
11
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Widescale evidence points to the involvement of glia and immune pathways in the progression of Alzheimer's disease (AD). AD-associated iPSC-derived glial cells show a diverse range of AD-related phenotypic states encompassing cytokine/chemokine release, phagocytosis and morphological profiles, but to date studies are limited to cells derived from PSEN1, APOE and APP mutations or sporadic patients. The aim of the current study was to successfully differentiate iPSC-derived microglia and astrocytes from patients harbouring an AD-causative PSEN2 (N141I) mutation and characterise the inflammatory and morphological profile of these cells. iPSCs from three healthy control individuals and three familial AD patients harbouring a heterozygous PSEN2 (N141I) mutation were used to derive astrocytes and microglia-like cells and cell identity and morphology were characterised through immunofluorescent microscopy. Cellular characterisation involved the stimulation of these cells by LPS and Aβ AD-derived astrocytes and microglia-like cells exhibited an atrophied and less complex morphological appearance than healthy controls. AD-derived astrocytes showed increased basal expression of GFAP, S100β and increased secretion and phagocytosis of Aβ Our study showed, for the first time, the differentiation and characterisation of iPSC-derived astrocytes and microglia-like cells harbouring a PSEN2 (N141I) mutation. PSEN2 (N141I)-mutant astrocytes and microglia-like cells presented with a 'primed' phenotype characterised by reduced morphological complexity, exaggerated pro-inflammatory cytokine secretion and altered Aβ
Sections du résumé
BACKGROUND
BACKGROUND
Widescale evidence points to the involvement of glia and immune pathways in the progression of Alzheimer's disease (AD). AD-associated iPSC-derived glial cells show a diverse range of AD-related phenotypic states encompassing cytokine/chemokine release, phagocytosis and morphological profiles, but to date studies are limited to cells derived from PSEN1, APOE and APP mutations or sporadic patients. The aim of the current study was to successfully differentiate iPSC-derived microglia and astrocytes from patients harbouring an AD-causative PSEN2 (N141I) mutation and characterise the inflammatory and morphological profile of these cells.
METHODS
METHODS
iPSCs from three healthy control individuals and three familial AD patients harbouring a heterozygous PSEN2 (N141I) mutation were used to derive astrocytes and microglia-like cells and cell identity and morphology were characterised through immunofluorescent microscopy. Cellular characterisation involved the stimulation of these cells by LPS and Aβ
RESULTS
RESULTS
AD-derived astrocytes and microglia-like cells exhibited an atrophied and less complex morphological appearance than healthy controls. AD-derived astrocytes showed increased basal expression of GFAP, S100β and increased secretion and phagocytosis of Aβ
CONCLUSION
CONCLUSIONS
Our study showed, for the first time, the differentiation and characterisation of iPSC-derived astrocytes and microglia-like cells harbouring a PSEN2 (N141I) mutation. PSEN2 (N141I)-mutant astrocytes and microglia-like cells presented with a 'primed' phenotype characterised by reduced morphological complexity, exaggerated pro-inflammatory cytokine secretion and altered Aβ
Identifiants
pubmed: 38178159
doi: 10.1186/s12974-023-02951-2
pii: 10.1186/s12974-023-02951-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Subventions
Organisme : National Health and Medical Research Council
ID : Program Grant (APP1132524), Principal Research Fellowship (APP1154692)
Informations de copyright
© 2023. The Author(s).
Références
Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet. 2009;18(R2):R137–45.
pubmed: 19808789
pmcid: 2758713
doi: 10.1093/hmg/ddp406
D’Avanzo C, Aronson J, Kim YH, Choi SH, Tanzi RE, Kim DY. Alzheimer’s in 3D culture: challenges and perspectives. BioEssays. 2015;37(10):1139–48.
pubmed: 26252541
pmcid: 4674791
doi: 10.1002/bies.201500063
De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10(16):1665–71.
pubmed: 11487570
doi: 10.1093/hmg/10.16.1665
Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–66.
pubmed: 11274343
doi: 10.1152/physrev.2001.81.2.741
Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, et al. Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(Pt 4):1143–54.
pubmed: 20375137
pmcid: 2850581
doi: 10.1093/brain/awq033
Ortiz-Virumbrales M, Moreno CL, Kruglikov I, Marazuela P, Sproul A, Jacob S, et al. CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2 N141I neurons. Acta Neuropathol Commun. 2017;5(1):1–20.
doi: 10.1186/s40478-017-0475-z
Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545–55.
pubmed: 15734686
doi: 10.1016/j.cell.2005.02.008
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8.
pubmed: 24162737
pmcid: 3896259
doi: 10.1038/ng.2802
Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461–7.
pubmed: 11513911
doi: 10.1016/S0140-6736(01)05625-2
Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(Pt 4):1252–64.
pubmed: 26984188
doi: 10.1093/brain/aww017
Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, et al. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol. 1998;152(4):983–92.
pubmed: 9546359
pmcid: 1858251
Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):492–510.
pubmed: 24269023
doi: 10.1016/j.neurobiolaging.2013.09.035
Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971(2):197–209.
pubmed: 12706236
doi: 10.1016/S0006-8993(03)02361-8
Senitz D, Reichenbach A, Smith TG Jr. Surface complexity of human neocortical astrocytic cells: changes with development, aging, and dementia. J Hirnforsch. 1995;36(4):531–7.
pubmed: 8568224
Dandrea MR, Reiser PA, Gumula NA, Hertzog BM, Andrade-Gordon P. Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer’s disease. Biotech Histochem. 2001;76(2):97–106.
pubmed: 11440311
doi: 10.1080/bih.76.2.97.106
Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin Neurosci. 1997;51(3):135–8.
pubmed: 9225377
doi: 10.1111/j.1440-1819.1997.tb02375.x
Shao Y, Gearing M, Mirra SS. Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. J Neuropathol Exp Neurol. 1997;56(4):376–81.
pubmed: 9100668
doi: 10.1097/00005072-199704000-00006
Drummond E, Wisniewski T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155–75.
pubmed: 28025715
doi: 10.1007/s00401-016-1662-x
Sloan SA, Darmanis S, Huber N, Khan TA, Birey F, Caneda C, et al. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron. 2017;95(4):779-90.e6.
pubmed: 28817799
pmcid: 5890820
doi: 10.1016/j.neuron.2017.07.035
Camp JG, Badsha F, Florio M, Kanton S, Gerber T, Wilsch-Brauninger M, et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci U S A. 2015;112(51):15672–7.
pubmed: 26644564
pmcid: 4697386
doi: 10.1073/pnas.1520760112
Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94(2):278-93.e9.
pubmed: 28426964
pmcid: 5482419
doi: 10.1016/j.neuron.2017.03.042
McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener. 2018;13(1):67.
pubmed: 30577865
pmcid: 6303871
doi: 10.1186/s13024-018-0297-x
Tcw J, Wang M, Pimenova AA, Bowles KR, Hartley BJ, Lacin E, et al. An efficient platform for astrocyte differentiation from human induced pluripotent stem cells. Stem Cell Reports. 2017;9(2):600–14.
pubmed: 28757165
pmcid: 5550034
doi: 10.1016/j.stemcr.2017.06.018
Jones VC, Atkinson-Dell R, Verkhratsky A, Mohamet L. Aberrant iPSC-derived human astrocytes in Alzheimer’s disease. Cell Death Dis. 2017;8(3): e2696.
pubmed: 28333144
pmcid: 5386580
doi: 10.1038/cddis.2017.89
Konttinen H, Cabral-da-Silva MEC, Ohtonen S, Wojciechowski S, Shakirzyanova A, Caligola S, et al. PSEN1DeltaE9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia. Stem Cell Rep. 2019;13(4):669–83.
doi: 10.1016/j.stemcr.2019.08.004
Konttinen H, Gureviciene I, Oksanen M, Grubman A, Loppi S, Huuskonen MT, et al. PPARbeta/delta-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1DeltaE9 astrocytes. Glia. 2019;67(1):146–59.
pubmed: 30453390
doi: 10.1002/glia.23534
Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen S, Gubert Olive M, et al. PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer’s disease. Stem Cell Reports. 2017;9(6):1885–97.
pubmed: 29153989
pmcid: 5785689
doi: 10.1016/j.stemcr.2017.10.016
Park J, Wetzel I, Marriott I, Dreau D, D’Avanzo C, Kim DY, et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease. Nat Neurosci. 2018;21(7):941–51.
pubmed: 29950669
pmcid: 6800152
doi: 10.1038/s41593-018-0175-4
Guttikonda SR, Sikkema L, Tchieu J, Saurat N, Walsh RM, Harschnitz O, et al. Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer’s disease. Nat Neurosci. 2021;24(3):343–54.
pubmed: 33558694
pmcid: 8382543
doi: 10.1038/s41593-020-00796-z
Xu M, Zhang L, Liu G, Jiang N, Zhou W, Zhang Y. Pathological changes in Alzheimer’s disease analyzed using induced pluripotent stem cell-derived human microglia-like cells. J Alzheimers Dis. 2019;67(1):357–68.
pubmed: 30562902
doi: 10.3233/JAD-180722
Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98(6):1141-54.e7.
pubmed: 29861287
pmcid: 6023751
doi: 10.1016/j.neuron.2018.05.008
Walsh DM, Thulin E, Minogue AM, Gustavsson N, Pang E, Teplow DB, et al. A facile method for expression and purification of the Alzheimer’s disease-associated amyloid beta-peptide. FEBS J. 2009;276(5):1266–81.
pubmed: 19175671
pmcid: 2702495
doi: 10.1111/j.1742-4658.2008.06862.x
Tian C, Liu Q, Ma K, Wang Y, Chen Q, Ambroz R, et al. Characterization of induced neural progenitors from skin fibroblasts by a novel combination of defined factors. Sci Rep. 2013;3:1345.
pubmed: 23439431
pmcid: 3581826
doi: 10.1038/srep01345
Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–67.
pubmed: 28636962
doi: 10.1016/j.immuni.2017.06.006
Ao Z, Cai H, Wu Z, Song S, Karahan H, Kim B, et al. Tubular human brain organoids to model microglia-mediated neuroinflammation. Lab Chip. 2021;21(14):2751–62.
pubmed: 34021557
pmcid: 8493632
doi: 10.1039/D1LC00030F
Liu W, Taso O, Wang R, Bayram S, Graham AC, Garcia-Reitboeck P, et al. Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. Hum Mol Genet. 2020;29(19):3224–48.
pubmed: 32959884
pmcid: 7689298
doi: 10.1093/hmg/ddaa209
Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 1998;57(1):1–9.
pubmed: 9630473
doi: 10.1016/S0169-328X(98)00040-0
Franco-Bocanegra DK, Gourari Y, McAuley C, Chatelet DS, Johnston DA, Nicoll JAR, et al. Microglial morphology in Alzheimer’s disease and after Abeta immunotherapy. Sci Rep. 2021;11(1):15955.
pubmed: 34354209
pmcid: 8342480
doi: 10.1038/s41598-021-95535-0
Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer’s disease. Brain Pathol. 2017;27(6):795–808.
pubmed: 27862631
doi: 10.1111/bpa.12456
Young K, Morrison H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using imageJ. J Vis Exp. 2018;136:e57648.
Brandenburg LO, Konrad M, Wruck CJ, Koch T, Lucius R, Pufe T. Functional and physical interactions between formyl-peptide-receptors and scavenger receptor MARCO and their involvement in amyloid beta 1–42-induced signal transduction in glial cells. J Neurochem. 2010;113(3):749–60.
pubmed: 20141570
doi: 10.1111/j.1471-4159.2010.06637.x
Xu X, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, et al. Prevention of beta-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. Stem Cell Res. 2013;10(2):213–27.
pubmed: 23305945
doi: 10.1016/j.scr.2012.11.005
Ferreira A, Sinjoanu RC, Nicholson A, Kleinschmidt S. Abeta toxicity in primary cultured neurons. Methods Mol Biol. 2011;670:141–53.
pubmed: 20967589
doi: 10.1007/978-1-60761-744-0_11
Veeraraghavalu K, Zhang C, Zhang X, Tanzi RE, Sisodia SS. Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of beta-amyloid by cells other than excitatory neurons. J Neurosci. 2014;34(10):3668–73.
pubmed: 24599465
pmcid: 3942582
doi: 10.1523/JNEUROSCI.5079-13.2014
McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease. Nat Commun. 2020;11(1):5370.
pubmed: 33097708
pmcid: 7584603
doi: 10.1038/s41467-020-19227-5
Bottcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019;22(1):78–90.
pubmed: 30559476
doi: 10.1038/s41593-018-0290-2
Carpenter AF, Carpenter PW, Markesbery WR. Morphometric analysis of microglia in Alzheimer’s disease. J Neuropathol Exp Neurol. 1993;52(6):601–8.
pubmed: 8229079
doi: 10.1097/00005072-199311000-00007
Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging. 2003;24(2):321–31.
pubmed: 12498966
doi: 10.1016/S0197-4580(02)00090-8
Beauquis J, Pavia P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer’s disease. Exp Neurol. 2013;239:28–37.
pubmed: 23022919
doi: 10.1016/j.expneurol.2012.09.009
Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. J Anat. 2012;221(3):252–62.
pubmed: 22738374
pmcid: 3458630
doi: 10.1111/j.1469-7580.2012.01536.x
Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia. 2010;58(7):831–8.
pubmed: 20140958
doi: 10.1002/glia.20967
Hyvarinen T, Hagman S, Ristola M, Sukki L, Veijula K, Kreutzer J, et al. Co-stimulation with IL-1beta and TNF-alpha induces an inflammatory reactive astrocyte phenotype with neurosupportive characteristics in a human pluripotent stem cell model system. Sci Rep. 2019;9(1):16944.
pubmed: 31729450
pmcid: 6858358
doi: 10.1038/s41598-019-53414-9
Escartin C, Guillemaud O, Carrillo-de Sauvage MA. Questions and (some) answers on reactive astrocytes. Glia. 2019;67(12):2221–47.
pubmed: 31429127
doi: 10.1002/glia.23687
Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010;31(4):578–90.
pubmed: 18586353
doi: 10.1016/j.neurobiolaging.2008.05.015
Kashon ML, Ross GW, O'Callaghan JP, Miller DB, Petrovitch H, Burchfiel CM, et al. Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis. 2004;6(6):595–604; discussion 73–81.
Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611–5.
pubmed: 2529544
pmcid: 298116
doi: 10.1073/pnas.86.19.7611
Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol. 1996;55(3):273–9.
pubmed: 8786385
doi: 10.1097/00005072-199603000-00002
Sheng JG, Mrak RE, Griffin WS. S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res. 1994;39(4):398–404.
pubmed: 7884819
doi: 10.1002/jnr.490390406
Marshak DR, Pesce SA, Stanley LC, Griffin WS. Increased S100 beta neurotrophic activity in Alzheimer’s disease temporal lobe. Neurobiol Aging. 1992;13(1):1–7.
pubmed: 1371849
doi: 10.1016/0197-4580(92)90002-F
Brozzi F, Arcuri C, Giambanco I, Donato R. S100B protein regulates astrocyte shape and migration via interaction with Src kinase: implications for astrocyte development, activation and tumor growth. J Biol Chem. 2009;284(13):8797–811.
pubmed: 19147496
pmcid: 2659238
doi: 10.1074/jbc.M805897200
Torres-Platas SG, Comeau S, Rachalski A, Bo GD, Cruceanu C, Turecki G, et al. Morphometric characterization of microglial phenotypes in human cerebral cortex. J Neuroinflammation. 2014;11:12.
pubmed: 24447857
pmcid: 3906907
doi: 10.1186/1742-2094-11-12
Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441–68.
pubmed: 28226226
pmcid: 8167938
doi: 10.1146/annurev-immunol-051116-052358
Salobrar-Garcia E, Rodrigues-Neves AC, Ramirez AI, de Hoz R, Fernandez-Albarral JA, Lopez-Cuenca I, et al. Microglial activation in the retina of a triple-transgenic Alzheimer’s disease mouse model (3xTg-AD). Int J Mol Sci. 2020;21(3):816.
pubmed: 32012676
pmcid: 7038053
doi: 10.3390/ijms21030816
Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with Abeta plaques in mouse models of Alzheimer’s disease. Aging Cell. 2014;13(4):584–95.
pubmed: 24641683
pmcid: 4326940
doi: 10.1111/acel.12210
Leyh J, Paeschke S, Mages B, Michalski D, Nowicki M, Bechmann I, et al. Classification of Microglial Morphological Phenotypes Using Machine Learning. Front Cell Neurosci. 2021;15: 701673.
pubmed: 34267628
pmcid: 8276040
doi: 10.3389/fncel.2021.701673
Nam H, Lee Y, Kim B, Lee JW, Hwang S, An HK, et al. Presenilin 2 N141I mutation induces hyperactive immune response through the epigenetic repression of REV-ERBalpha. Nat Commun. 2022;13(1):1972.
pubmed: 35418126
pmcid: 9008044
doi: 10.1038/s41467-022-29653-2
Fung S, Smith CL, Prater KE, Case A, Green K, Osnis L, et al. Early-onset familial Alzheimer disease variant PSEN2 N141I heterozygosity is associated with altered microglia phenotype. J Alzheimers Dis. 2020;77(2):675–88.
pubmed: 32741831
pmcid: 7592656
doi: 10.3233/JAD-200492
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y). 2018;4:575–90.
pubmed: 30406177
doi: 10.1016/j.trci.2018.06.014
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–72.
pubmed: 25991443
doi: 10.1038/nrn3880
Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci. 2001;21(3):812–22.
pubmed: 11157067
pmcid: 6762321
doi: 10.1523/JNEUROSCI.21-03-00812.2001
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–18.
pubmed: 23296339
pmcid: 3726719
doi: 10.1038/nrneurol.2012.263
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.
pubmed: 8346443
doi: 10.1126/science.8346443
den Hartigh LJ, Altman R, Hutchinson R, Petrlova J, Budamagunta MS, Tetali SD, et al. Postprandial apoE isoform and conformational changes associated with VLDL lipolysis products modulate monocyte inflammation. PLoS ONE. 2012;7(11): e50513.
doi: 10.1371/journal.pone.0050513
Hatters DM, Budamagunta MS, Voss JC, Weisgraber KH. Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. J Biol Chem. 2005;280(40):34288–95.
pubmed: 16076841
doi: 10.1074/jbc.M506044200
Maezawa I, Maeda N, Montine TJ, Montine KS. Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation. 2006;3:10.
pubmed: 16603079
pmcid: 1502133
doi: 10.1186/1742-2094-3-10
Ophir G, Meilin S, Efrati M, Chapman J, Karussis D, Roses A, et al. Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. Neurobiol Dis. 2003;12(1):56–64.
pubmed: 12609489
doi: 10.1016/S0969-9961(02)00005-0
Fraga VG, Magalhaes CA, Loures CMG, de Souza LC, Guimaraes HC, Zauli DAG, et al. Inflammatory and pro-resolving mediators in frontotemporal dementia and Alzheimer’s disease. Neuroscience. 2019;421:123–35.
pubmed: 31654714
doi: 10.1016/j.neuroscience.2019.09.008
Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, Peterson PK, et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol. 1998;160(4):1944–8.
pubmed: 9469457
doi: 10.4049/jimmunol.160.4.1944
Araujo DM, Cotman CW. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res. 1993;600(1):49–55.
pubmed: 8422590
doi: 10.1016/0006-8993(93)90400-H
Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishii T, McGeer PL. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol. 1993;85(6):628–34.
pubmed: 8337942
doi: 10.1007/BF00334673
Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer’s disease. Am J Pathol. 1994;144(1):104–16.
pubmed: 7904796
pmcid: 1887111
Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. Microglial cells around amyloid plaques in Alzheimer’s disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett. 1989;101(3):288–92.
pubmed: 2549464
doi: 10.1016/0304-3940(89)90547-8
Noe CR, Noe-Letschnig M, Handschuh P, Noe CA, Lanzenberger R. Dysfunction of the Blood-Brain Barrier-A Key Step in Neurodegeneration and Dementia. Front Aging Neurosci. 2020;12:185.
pubmed: 32848697
pmcid: 7396716
doi: 10.3389/fnagi.2020.00185
Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis. 2007;26(1):27–35.
pubmed: 17270454
doi: 10.1016/j.nbd.2006.11.011
Clark PR, Manes TD, Pober JS, Kluger MS. Increased ICAM-1 expression causes endothelial cell leakiness, cytoskeletal reorganization and junctional alterations. J Invest Dermatol. 2007;127(4):762–74.
pubmed: 17195014
doi: 10.1038/sj.jid.5700670
Rentzos M, Michalopoulou M, Nikolaou C, Cambouri C, Rombos A, Dimitrakopoulos A, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci. 2005;228(2):129–35.
pubmed: 15694193
doi: 10.1016/j.jns.2004.11.001
Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867–77.
pubmed: 30054439
pmcid: 6133624
doi: 10.1212/WNL.0000000000006082
Perez-Nievas BG, Johnson L, Beltran-Lobo P, Hughes MM, Gammallieri L, Tarsitano F, et al. Astrocytic C-X-C motif chemokine ligand-1 mediates beta-amyloid-induced synaptotoxicity. J Neuroinflammation. 2021;18(1):306.
pubmed: 34963475
pmcid: 8715604
doi: 10.1186/s12974-021-02371-0
Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J Neurochem. 1999;72(5):2215–8.
pubmed: 10217305
doi: 10.1046/j.1471-4159.1999.0722215.x
Nasiri E, Sankowski R, Dietrich H, Oikonomidi A, Huerta PT, Popp J, et al. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer’s disease. Mol Med. 2020;26(1):34.
pubmed: 32303185
pmcid: 7164357
doi: 10.1186/s10020-020-00163-5
Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Pirttila T. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging. 2009;30(2):198–209.
pubmed: 17658666
doi: 10.1016/j.neurobiolaging.2007.06.006
Srinivasan K, Friedman BA, Etxeberria A, Huntley MA, van der Brug MP, Foreman O, et al. Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Rep. 2020;31(13): 107843.
pubmed: 32610143
pmcid: 7422733
doi: 10.1016/j.celrep.2020.107843
Monaco G, van Dam S, Casal Novo Ribeiro JL, Larbi A, de Magalhaes JP. A comparison of human and mouse gene co-expression networks reveals conservation and divergence at the tissue, pathway and disease levels. BMC Evol Biol. 2015;15:259.
pubmed: 26589719
pmcid: 4654840
doi: 10.1186/s12862-015-0534-7
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774.
pubmed: 21148344
pmcid: 3073454
doi: 10.1126/science.1197623
Reich M, Paris I, Ebeling M, Dahm N, Schweitzer C, Reinhardt D, et al. Alzheimer’s risk gene TREM2 determines functional properties of new type of human iPSC-derived microglia. Front Immunol. 2020;11: 617860.
pubmed: 33613545
doi: 10.3389/fimmu.2020.617860
Hall-Roberts H, Agarwal D, Obst J, Smith TB, Monzon-Sandoval J, Di Daniel E, et al. TREM2 Alzheimer’s variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages. Alzheimers Res Ther. 2020;12(1):151.
pubmed: 33198789
pmcid: 7667762
doi: 10.1186/s13195-020-00709-z